Hillsdale Investment Management’s Travere Therapeutics TVTX Stock Holding History

Hillsdale Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.42M	Buy	182,320 +5,100	+3%	+$152K	0.15%	172
2025 Q4	$6.77M	Sell	177,220 -1,180	-0.7%	-$38.4K	0.19%	138
2025 Q3	$4.26M	Buy	178,400 +15,000	+9%	+$282K	0.13%	229
2025 Q2	$2.42M	Buy	+163,400	New	+$2.71M	0.09%	262
2021 Q1	–	Sell	-47,900	Closed	-$1.31M	–	682
2020 Q4	$1.31M	Hold	47,900	–	–	0.12%	168
2020 Q3	$884K	Sell	47,900 -400	-0.8%	-$7.78K	0.09%	206
2020 Q2	$986K	Buy	+48,300	New	+$769K	0.09%	180

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hillsdale Investment Management's TVTX Position: Q1 2026 in Review

Hillsdale Investment Management increased its Travere Therapeutics (TVTX) stake by 2.9% in Q1 2026, buying an estimated $152K and bringing the position to 182,320 shares worth $5.42M. The position accounts for 0.15% of the portfolio, ranked #172.

Hillsdale Investment Management first reported a position in TVTX in Q2 2020 and has held it in 7 quarters since. The position peaked at $6.77M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Hillsdale Investment Management held 182,320 shares of Travere Therapeutics worth $5.42M as of Q1 2026.
Hillsdale Investment Management bought 5,100 Travere Therapeutics shares in Q1 2026, an estimated $152K.
Travere Therapeutics made up 0.15% of Hillsdale Investment Management's portfolio in Q1 2026, its #172 holding.
Hillsdale Investment Management first reported a position in Travere Therapeutics in Q2 2020 and has held it in 7 quarters since.
Hillsdale Investment Management's Travere Therapeutics position peaked at $6.77M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.